我要投票 21金维他在补铁锌硒行业中的票数:1160
· 外 推 电 报 ·
2025-08-22 08:45:36 星期五

【21金维他是哪个国家的品牌?】

21金维他是什么牌子?「21金维他」是杭州赛诺菲民生健康药业有限公司旗下著名品牌。该品牌发源于浙江,由创始人张海敏在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力21金维他品牌出海!将品牌入驻外推网,定制21金维他品牌推广信息,可以显著提高21金维他产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

21金维他,1984年上市,是中国率先上市的多维元素产品。根据中国人营养状况和饮食习惯科学配比,均衡补充人体所需的21维生素和矿物质,采用国际一流生产线生产的健康产品。

“21金维他”是一种主要原料由21种维生素和微量元素组成的药品,是一种高级的维生素补充剂。21金维他里面含有维生素C和E,维生素C可以美白,增强抵抗力,抗衰老,维生素E有软化血管,抗衰老,美白,可以用于美容,祛除一定的斑痕。

杭州民生药业有限公司创建于1926年,是中国最早的四大西药厂之一。80余年来,民生药业一直专注于西药制药产业,见证了中国整个西药制药的历史。2006年被商务部评为第一批“中华老字号”企业。

公司主要生产处方药(抗肿瘤药、抗乙肝、心血管类)、OTC(含维生素和保健品类)、大输液(包括特种输液)以及原料药等四大品类的品种。21金维他在2004年被认定为“中国驰名商标”,并确立了在国内多维元素补充剂市场的领军品牌地位。另外公司在抗肿瘤及大输液等领域享有较高的市场声誉。

公司具有较强的产品开发能力和先进的质量保证体系。粉针剂、冻干粉针剂、大容量注射剂和片剂已获药品GMP证书。同时公司被杭州市政府有关部门确定为高效化学原料及各类新型制剂的研究和生产基地的高新技术企业。

80余年的积累和发展,民生药业成为了一家专业化、负责任的现代化制药公司,公司在2002年至2006年间成功实施了跳跃式发展战略;从2007年开始全面实施的国际化发展战略,将引领企业走向新的辉煌。打造一个经久不衰、生生不息、充满青春活力的百年民生是我们的追求!

杭州赛诺菲民生健康药业有限公司成立于2010年,是由全球领先的多元化医药健康企业赛诺菲与杭州民生药业集团共同组建的健康药业领域合资企业。这标志着赛诺菲正式进军充满活力的中国非处方药市场,同时也是全球第二大的非处方药市场。

作为全球领先的多元化医药健康企业,赛诺菲在健康药业领域通过不断并购,扩大其在全球的实力。进入中国健康药业市场成为赛诺菲支持中国预防保健事业的又一支柱。赛诺菲与长期合作的伙伴民生药业成立合资企业,旨在使21金维他®等品牌覆盖到各个市场,让更多的中国百姓享受到健康保障。

英文翻译:Kingvita, launched in 1984, is the first multi-dimensional element product to be launched in China. According to the scientific proportion of Chinese Nutrition and diet habits, we should supplement the 21 vitamins and minerals needed by human body in a balanced way, and adopt the health products produced by the world-class production line. "21 jinvita" is a kind of medicine composed of 21 kinds of vitamins and microelements, which is a kind of advanced vitamin supplement. Jinvita contains vitamin C and E. vitamin C can whiten, enhance resistance and resist aging. Vitamin E can soften blood vessels, resist aging and whiten. It can be used for beauty and remove certain spots. Founded in 1926, Hangzhou Minsheng Pharmaceutical Co., Ltd. is one of the first four Western pharmaceutical factories in China. For more than 80 years, Minsheng pharmaceutical industry has been focusing on Western pharmaceutical industry, witnessing the history of the whole western pharmaceutical industry in China. In 2006, it was awarded the first batch of "Chinese time-honored brand" enterprises by the Ministry of Commerce. The company mainly produces prescription drugs (anti-tumor drugs, anti hepatitis B drugs, cardiovascular drugs), OTC (including vitamins and health care products), large infusion (including special infusion) and APIs. In 2004, kingvita was recognized as "China's well-known trademark" and established its leading brand position in the domestic multi-dimensional element supplement market. In addition, the company enjoys a high market reputation in the fields of anti-tumor and infusion. The company has strong product development ability and advanced quality assurance system. Powder injection, freeze-dried powder injection, large volume injection and tablet have obtained GMP certificate. At the same time, the company is determined by the relevant departments of Hangzhou municipal government as a high-tech enterprise in the research and production base of high-efficiency chemical raw materials and various new preparations. With more than 80 years of accumulation and development, Minsheng pharmaceutical industry has become a professional and responsible modern pharmaceutical company. From 2002 to 2006, Minsheng pharmaceutical successfully implemented the leaping development strategy. The international development strategy, which has been fully implemented since 2007, will lead the enterprise to a new glory. It is our pursuit to build a centenary people's livelihood that is enduring, endless and full of youth and vitality! Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., founded in 2010, is a joint venture in the field of health pharmaceutical jointly established by Sanofi, a global leading diversified pharmaceutical and health enterprise, and Hangzhou Minsheng Pharmaceutical Group. This marks Sanofi's official entry into the dynamic Chinese over-the-counter drug market, which is also the second largest over-the-counter drug market in the world. As a leading diversified medical and health enterprise in the world, Sanofi expands its global strength through continuous M & A in the field of health medicine. Entering the Chinese health pharmaceutical market has become another pillar of Sanofi's support for China's prevention and health care. Sanofi has set up a joint venture with Minsheng pharmaceutical, a long-term partner, aiming to make 21 jinvita ® and other brands reach all markets and more Chinese people enjoy health protection.

本文链接: https://www.waitui.com/brand/0d30c126b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

“创新+国际化”步伐加快,多家创新药企“中考成绩”亮眼

记者梳理发现,截至目前,百济神州、翰森制药等多家创新药企披露上半年业绩情况,创新药收入情况、研发管线进展、出海规划等成为市场关注焦点。业内人士表示,当前我国创新药相关企业已经实现从量变到质变的转化,逐渐从“跟跑者”到“引领者”。创新药板块景气度有望持续,“创新+国际化”步伐逐渐加快,成为医药板块的核心方向。(中证报)

46分钟前

商业化带动需求提升,eVTOL动力电池路径渐明

随着eVTOL(电动垂直起降飞行器)订单密集落地,其商业化进程不断加速。与此同时,GWh级别的电池需求也逐渐显现。专家表示,面对航空级电池更为严格的要求,固态电池因兼具高能量密度与高安全性的特点,应用潜力较大,或将成为eVTOL厂商的核心选择。不过,固态电池在技术、供应链、成本等方面仍存在亟待突破的难题,其商业化之路依然漫长。在此背景下,混动路线成为部分厂商关注的焦点。业内预计,在未来相当长一段时间,混动路线会在eVTOL领域占有一席之地。(上证报)

46分钟前

马斯克称SpaceX明年收入将超过NASA预算

马斯克周四在X平台上发帖称:“SpaceX今年将从NASA获得的收入大约是10亿美元,约占150亿美元总收入的7%。”一位用户评论称:“很快,SpaceX的收入可能就会超过NASA的全部预算。”马斯克回应称:“明年。”根据美国白宫今年5月份公布的2026财年联邦支出预算提案,美国国家航空航天局(NASA)2026财年分配预算为188亿美元,较2025财年实际获得的249亿美元下降了近25%。(新浪财经)

46分钟前

稀土价格快速走高,稀土板块迎来业绩反转

稀土主要品种价格快速走高,8月以来平均上涨超过10万元/吨。与此同时,永磁体价格也快速走高,钕铁硼N35最新报价144.5元/千克,月内涨幅10.7%,年内涨幅51.3%。2024年,稀土价格大幅走低,A股稀土板块业绩暴跌,在业绩低基数和稀土价格走高的双重影响下,今年稀土板块迎来业绩反转。据数据宝统计,截至8月21日,已有14家稀土永磁个股发布上半年业绩数据(含预告、快报和年报),多数公司业绩预增或扭亏。龙头股北方稀土净利润更是同比暴增超18倍。(证券时报)

46分钟前

特斯拉未及时提交事故报告,美监管部门对其发起审查

美国国家公路交通安全管理局(NHTSA)下属缺陷调查办公室当地时间8月19日称,特拉斯未按照规定及时提交事故报告,NHTSA因此将启动审查,评估潜在报告延迟的原因、延迟的范围,以及特斯拉为解决这些问题所采取的缓解措施。作为此次审查的一部分,NHTSA还将评估是否仍有先前事故的报告未提交,以及已提交的报告是否包含所有必要且可用的数据。(界面)

46分钟前

本页详细列出关于21金维他的品牌信息,含品牌所属公司介绍,21金维他所处行业的品牌地位及优势。
咨询